Fertility preservation options for transfeminine adolescents
Succesfull Fertility Preservation for Transfeminine Adolescents Via Semen Cryopreservation or Testicular Sperm Extraction
This study looks at how transfeminine teens and their parents decide on options to preserve fertility, like sperm extraction and freezing, and what factors affect their success.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 10 Years to 18 Years |
| Sex | Male |
| Sponsor | Amsterdam UMC, location VUmc Academic / other |
| Locations | 2 sites (Amsterdam and 1 other locations) |
| Trial ID | NCT06400199 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to identify key factors that influence the success of testicular sperm extraction (TESE) and semen cryopreservation in transfeminine adolescents. It evaluates the decision-making process and experiences of these adolescents and their parents when considering fertility preservation, particularly in relation to the timing of puberty suppression. Participants will provide medical data and complete questionnaires to help understand their experiences and the optimal timing for these procedures.
Who should consider this trial
Good fit: Ideal candidates are transfeminine adolescents who wish to preserve their fertility before starting puberty suppression or after temporarily discontinuing it.
Not a fit: Patients who are already in Tanner stage 4 or 5 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide transfeminine adolescents with better options for preserving their fertility before undergoing hormone therapy.
How similar studies have performed: While there is limited data on this specific approach, similar studies in fertility preservation for transgender individuals have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Before start of puberty suppresion with a wish for fertility preservation * After discontinuing puberty suppersion before the start of hormone therapy Exclusion Criteria: * Tanner stage \> 4/5
Where this trial is running
Amsterdam and 1 other locations
- Amsterdam UMC, location AMC — Amsterdam, Netherlands (Recruiting)
- Amsterdam UMC, Location VU Medical Center — Amsterdam, Netherlands (Recruiting)
Study contacts
- Principal investigator: Judith Huirne, MD, PHD, PROF — Amsterdam UMC
- Study coordinator: Tessa Stolk, MD
- Email: t.h.stolk@amsterdamumc.nl
- Phone: +31623844827
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.